Cspc Pharmaceutical
Cspc Pharmaceutical Group Limited, commonly referred to as Cspc, is a leading player in the pharmaceutical industry, headquartered in Hong Kong. Established in 1997, the company has made significant strides in research and development, focusing on innovative drug formulations and high-quality generic medicines. With a strong presence in both domestic and international markets, Cspc operates extensively across Asia, Europe, and North America. Cspc's core offerings include a diverse range of prescription drugs, over-the-counter products, and active pharmaceutical ingredients (APIs). The company is particularly noted for its advancements in oncology, cardiovascular, and central nervous system therapies, setting it apart through its commitment to quality and efficacy. Recognised for its robust market position, Cspc has achieved numerous accolades, solidifying its reputation as a trusted name in healthcare.
DitchCarbon Score
How does Cspc Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cspc Pharmaceutical's score of 33 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cspc Pharmaceutical's reported carbon emissions
In 2023, Cspc Pharmaceutical, headquartered in Hong Kong, reported total carbon emissions of approximately 1,137,042,000 kg CO2e. This figure includes 564,429,000 kg CO2e from Scope 1 emissions and 572,613,000 kg CO2e from Scope 2 emissions, resulting in a combined total for Scope 1 and 2 of about 1,081,261,000 kg CO2e. Comparatively, in 2022, the company recorded total emissions of about 1,081,261,000 kg CO2e, with Scope 1 emissions at 663,224,000 kg CO2e and Scope 2 emissions at 418,037,000 kg CO2e. This indicates a slight increase in total emissions from 2022 to 2023. Cspc Pharmaceutical has set ambitious reduction targets for its greenhouse gas emissions. The company aims to reduce emissions per unit of revenue by 53% for the period 2024-2026, and by 56% for 2027-2028, with a further target of a 60% reduction for 2029-2030. These targets apply to both Scope 1 and Scope 2 emissions, demonstrating a commitment to improving operational efficiency and reducing carbon intensity. Additionally, Cspc Pharmaceutical has committed to aligning its climate strategy with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) to better identify and manage climate-related risks and opportunities. This commitment is part of their broader strategy to minimise their carbon footprint from operational activities. Overall, Cspc Pharmaceutical is actively working towards significant emissions reductions while enhancing its sustainability practices in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 1,108,844,970 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 53,566,610 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 44,547,340 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cspc Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
